# Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation

Study · id `cardio:ct-nct05462145` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05462145](<https://clinicaltrials.gov/study/NCT05462145>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05462145

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 549 participants.

## Technical summary

Registry record NCT05462145. Allocation not applicable; no masking; primary purpose treatment. Start 2023-03-09 (actual); primary completion 2029-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 549 participants (planned count; ClinicalTrials.gov record NCT05462145, source copy `cardio:ctgov-nct05462145-2026-10-06`, retrieved 2026-10-26)
- Started: 2023-03-09 (actual) (ClinicalTrials.gov record NCT05462145, source copy `cardio:ctgov-nct05462145-2026-10-06`, retrieved 2026-10-26)
- Primary completion: 2029-03 (anticipated) (ClinicalTrials.gov record NCT05462145, source copy `cardio:ctgov-nct05462145-2026-10-06`, retrieved 2026-10-26)
- Completion: 2029-03 (anticipated) (ClinicalTrials.gov record NCT05462145, source copy `cardio:ctgov-nct05462145-2026-10-06`, retrieved 2026-10-26)
- Countries: United States; Canada; Czechia; Germany (ClinicalTrials.gov record NCT05462145, source copy `cardio:ctgov-nct05462145-2026-10-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05462145-2026-10-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation
- Acronym: PULSAR
- Condition: Paroxysmal Atrial Fibrillation
- Condition: Persistent Atrial Fibrillation
- Intervention (Device): Globe Pulsed Field System
- Lead sponsor: Kardium Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Kardium Inc. (`cardio:org-kardium-inc`)

## Provenance

Content hash: a28cb3e6abe93e77984de05724e4a8ef9cff3ff1e88ebe6160945e597681e8ae
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
